Antibiotic Pipeline Profile: Balancing Broad Spectrum And Limited Use

Broad spectrum antibiotic candidates for hospital use dominate the late-stage pipeline under the US FDA's Qualified Infectious Disease Product (QIDP) program, despite efforts to target limited populations of patients and pathogens.

Broad spectrum systemic antibiotics for hospitalized patients will likely continue to account for most of the novel agents approved under the Qualified Infectious Disease Product (QIDP) designation for the near future, according to data from Scrip sister publication The Pink Sheet's FDA Performance Tracker.

Antibiotic Pipeline Series

This is the second article in a series about the antibiotic development pipeline.

For the first article regarding progress and challenges following the US FDA's establishment of the QIDP program, see:

Broad spectrum agents remain the best option for acutely ill patients who cannot wait to begin treatment while bacteria are being identified, even as more targeted approaches to anti-infective therapy advance with the hope of slowing the development of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.